Eli Lilly’s Phase 3 SEQUOIA trial fails to meet primary endpoint
Category: #health  By Mateen Dalal  Date: 2019-10-18
  • share
  • Twitter
  • Facebook
  • LinkedIn

Eli Lilly’s Phase 3 SEQUOIA trial fails to meet primary endpoint

Metastatic pancreatic cancer (MPC) is one of the most fatal cancers in the world. Pancreatic cancer is slated to be the third leading cause of cancer death in the U.S. and is expected to become the second leading cause of cancer-related death over the coming years. As this is an aggressive cancer, there is a dire need for new treatments to improve clinical outcomes for pancreatic cancer patients.

Eli Lilly and Company has reportedly declared top-line results from its Phase 3 SEQUOIA trial assessing pegilodecakin plus FOLFOX compared to FOLFOX alone in patients who are suffering from metastatic pancreatic cancer whose disease has progressed on one prior gemcitabine-containing regimen. However, the clinical trial failed to meet its primary endpoint of overall survival.

Sources close to the study cite that the most common Grade 3/4 adverse events happening at a higher rate (>5% difference) during SEQUOIA clinical trial were thrombocytopenia, fatigue, neutropenia, and anemia. In-depth safety and efficiency results would be presented at future medical meetings.

Maura Dickler, Vice President, Late Phase Development, Lilly Oncology, said that pancreatic cancer is one most difficult cancer to treat and there had been very few treatment advancements in the later-line metastatic setting.

The company is disappointed by the outcome of this clinical trial, however, is grateful to the patients, researchers, and investigators who took part in it. Dickler added that the company will be focusing on upcoming clinical trial results in lung cancer, taking lessons from these studies and would understand pegilodecakin's novel mechanism of action in cancer immunotherapy in a better way.

Reports cite that, for the next stage of pegilodecakin's clinical trial, Eli Lilly is focusing on conducting studies in NSCLC and assessing biomarkers for the next stage of pegilodecakin's clinical development. The company will also be focusing on other tumor types like renal cell carcinoma where molecules had shown positive activity.

Source Credit - https://investor.lilly.com/news-releases/news-release-details/lilly-announces-phase-3-study-patients-metastatic-pancreatic

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

British Airways suspends 30,000 employees amid growing COVID-19 crisis
British Airways suspends 30,000 employees amid growing COVID-19 crisis
By Mateen Dalal

British Airways, a renowned British airline, has reportedly reached a new agreement with unions according to which over 30,000 ground staff and cabin crew members would be suspended. This is the most dramatic move ever to take place in the commercial...

Bunnings Warehouse launches a range of fitness equipment online
Bunnings Warehouse launches a range of fitness equipment online
By Mateen Dalal

The retail giant will be selling equipment like rowing machine, treadmills, cross trainers, and exercise bikes starting at $349. Bunnings Warehouse, an Australian household hardware chain, has reportedly launched an affordable range of fit...

Home Depot to reserve masks for frontline healthcare professionals
Home Depot to reserve masks for frontline healthcare professionals
By Mateen Dalal

As COVID-19 cases continue to soar in America, medical professionals on the front lines are facing a shortage of masks and other protective equipment. To cope up with increasing demand, The Home Depot Inc., one of the leading home improvement retaile...